Loading clinical trials...
Loading clinical trials...
A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy
Conditions
Interventions
everolimus
lenalidomide
+5 more
Locations
2
United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
January 10, 2011
Primary Completion Date
February 28, 2015
Completion Date
February 13, 2020
Last Updated
October 22, 2020
NCT07388563
NCT06561048
NCT04195633
NCT04925609
NCT00336063
NCT03278782
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions